{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Recurrent+Malignant+Skin+Neoplasm&page=2", "query": { "condition": "Recurrent Malignant Skin Neoplasm", "page": 2 }, "page_size": 10 }, "pagination": { "page": 2, "page_size": 10, "total_count": 10, "total_pages": 1, "next_page_url": null, "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Recurrent+Malignant+Skin+Neoplasm&page=1&page_size=10" }, "source": "remote", "last_synced_at": "2026-05-22T07:49:36.560Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT04007744", "title": "Sonidegib and Pembrolizumab in Treating Patients With Advanced Solid Tumors", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Clinical Stage III Cutaneous Melanoma AJCC v8", "Clinical Stage III Gastric Cancer AJCC v8", "Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8", "Clinical Stage IV Cutaneous Melanoma AJCC v8", "Clinical Stage IV Gastric Cancer AJCC v8", "Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8", "Locally Advanced Gastric Adenocarcinoma", "Locally Advanced Gastroesophageal Junction Adenocarcinoma", "Locally Advanced Urothelial Carcinoma", "Metastatic Gastric Adenocarcinoma", "Metastatic Gastroesophageal Junction Adenocarcinoma", "Metastatic Head and Neck Squamous Cell Carcinoma", "Metastatic Lung Non-Small Cell Carcinoma", "Metastatic Malignant Solid Neoplasm", "Metastatic Melanoma", "Metastatic Urothelial Carcinoma", "Recurrent Head and Neck Squamous Cell Carcinoma", "Refractory Lung Non-Small Cell Carcinoma", "Stage IV Cutaneous Squamous Cell Carcinoma of the Head and Neck AJCC v8", "Stage IV Lung Cancer AJCC v8", "Unresectable Malignant Solid Neoplasm", "Unresectable Melanoma" ], "interventions": [ { "name": "Pembrolizumab", "type": "BIOLOGICAL" }, { "name": "Sonidegib", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Mayo Clinic", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 36, "start_date": "2020-02-13", "completion_date": "2027-07-02", "has_results": false, "last_update_posted_date": "2026-03-18", "last_synced_at": "2026-05-22T07:49:36.560Z", "location_count": 3, "location_summary": "Scottsdale, Arizona • Jacksonville, Florida • Rochester, Minnesota", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Jacksonville", "state": "Florida" }, { "city": "Rochester", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT04007744" }, { "nct_id": "NCT03075553", "title": "Nivolumab in Treating Patients With Relapsed or Refractory Peripheral T-cell Lymphoma", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Blastic Plasmacytoid Dendritic Cell Neoplasm", "Hepatosplenic T-Cell Lymphoma", "HTLV-1 Infection", "NK-Cell Lymphoma, Unclassifiable", "Primary Systemic Anaplastic Large Cell Lymphoma, ALK-Negative", "Recurrent Adult T-Cell Leukemia/Lymphoma", "Recurrent Anaplastic Large Cell Lymphoma", "Recurrent Angioimmunoblastic T-cell Lymphoma", "Recurrent Enteropathy-Associated T-Cell Lymphoma", "Recurrent Mycosis Fungoides", "Refractory Adult T-Cell Leukemia/Lymphoma", "Refractory Anaplastic Large Cell Lymphoma", "Refractory Angioimmunoblastic T-cell Lymphoma", "Refractory Enteropathy-Associated T-Cell Lymphoma", "Refractory Mycosis Fungoides", "Refractory Nasal Type Extranodal NK/T-Cell Lymphoma", "Refractory Peripheral T-Cell Lymphoma, Not Otherwise Specified" ], "interventions": [ { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Nivolumab", "type": "BIOLOGICAL" } ], "intervention_types": [ "OTHER", "BIOLOGICAL" ], "sponsor": "Mayo Clinic", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 12, "start_date": "2017-05-17", "completion_date": "2019-05-29", "has_results": true, "last_update_posted_date": "2020-04-21", "last_synced_at": "2026-05-22T07:49:36.560Z", "location_count": 1, "location_summary": "Rochester, Minnesota", "locations": [ { "city": "Rochester", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT03075553" }, { "nct_id": "NCT04985604", "title": "Tovorafenib (DAY101) Monotherapy for Patients With Melanoma and Other Solid Tumors", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Melanoma", "Solid Tumor", "CRAF Gene Amplification", "RAF1 Gene Amplification", "BRAF Gene Fusion", "BRAF Fusion", "CRAF Gene Fusion", "CRAF Fusion", "RAF1 Gene Fusion", "RAF1 Fusion", "Thyroid Cancer, Papillary", "Spitzoid Melanoma", "Pilocytic Astrocytoma", "Pilocytic Astrocytoma, Adult", "Non Small Cell Lung Cancer", "Non-Small Cell Adenocarcinoma", "Colorectal Cancer", "Pancreatic Acinar Carcinoma", "Spitzoid Malignant Melanoma", "Bladder Cancer", "Bladder Urothelial Carcinoma", "MAP Kinase Family Gene Mutation", "RAF Mutation" ], "interventions": [ { "name": "Tovorafenib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Day One Biopharmaceuticals, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Years", "maximum_age": null, "sex": "ALL", "summary": "12 Years and older" }, "enrollment_count": 23, "start_date": "2021-07-15", "completion_date": "2024-07-08", "has_results": true, "last_update_posted_date": "2025-10-02", "last_synced_at": "2026-05-22T07:49:36.560Z", "location_count": 8, "location_summary": "Los Angeles, California • Newport Beach, California • Aurora, Colorado + 5 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Newport Beach", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Jacksonville", "state": "Florida" }, { "city": "Indianapolis", "state": "Indiana" } ], "official_url": "https://clinicaltrials.gov/study/NCT04985604" }, { "nct_id": "NCT05130255", "title": "GD2-SADA:177Lu-DOTA Complex in Patients With Solid Tumors Known to Express GD2", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "SCLC", "Malignant Melanoma", "Sarcoma", "High Risk Neuroblastoma" ], "interventions": [ { "name": "GD2-SADA:177Lu-DOTA Complex", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Y-mAbs Therapeutics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "16 Years", "maximum_age": null, "sex": "ALL", "summary": "16 Years and older" }, "enrollment_count": 60, "start_date": "2022-11-17", "completion_date": "2027-04", "has_results": false, "last_update_posted_date": "2024-10-02", "last_synced_at": "2026-05-22T07:49:36.560Z", "location_count": 8, "location_summary": "Scottsdale, Arizona • Duarte, California • Chicago, Illinois + 5 more", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Duarte", "state": "California" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Grand Rapids", "state": "Michigan" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT05130255" }, { "nct_id": "NCT05645744", "title": "Long-term Follow-up Study in Patients Previously Treated With a Mustang Bio CAR-T Cell Investigational Product.", "overall_status": "TERMINATED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)", "Chronic Lymphocytic Leukemia in Relapse", "Small Lymphocytic Lymphoma, Relapsed", "Waldenstrom's Macroglobulinemia Recurrent", "Follicular B-cell Non-Hodgkin's Lymphoma", "B-cell Lymphoma Refractory", "Mantle Cell Lymphoma Recurrent", "Hairy Cell Leukemia", "Diffuse Large B Cell Lymphoma", "Waldenstrom's Macroglobulinemia Refractory", "Mantle Cell Lymphoma Refractory" ], "interventions": [ { "name": "Prior MB-102 CAR-T cell investigational product.", "type": "BIOLOGICAL" }, { "name": "Prior MB-106 CAR-T cell investigational product.", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Mustang Bio", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 3, "start_date": "2021-09-29", "completion_date": "2024-04-12", "has_results": false, "last_update_posted_date": "2024-07-22", "last_synced_at": "2026-05-22T07:49:36.560Z", "location_count": 5, "location_summary": "Orange, California • Boston, Massachusetts • Rochester, New York + 2 more", "locations": [ { "city": "Orange", "state": "California" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Rochester", "state": "New York" }, { "city": "Cleveland", "state": "Ohio" }, { "city": "Seattle", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT05645744" }, { "nct_id": "NCT06325748", "title": "SENTI-202: Off-the-shelf Logic Gated CAR NK Cell Therapy in Adults With CD33 and/or FLT3 Blood Cancers Including AML/MDS", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "AML/MDS", "CD33 Expressing Hematological Malignancies", "FLT3 Expressing Hematological Malignancies" ], "interventions": [ { "name": "SENTI-202", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Senti Biosciences", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "74 Years", "sex": "ALL", "summary": "18 Years to 74 Years" }, "enrollment_count": 21, "start_date": "2024-04-22", "completion_date": "2040-08", "has_results": false, "last_update_posted_date": "2026-02-12", "last_synced_at": "2026-05-22T07:49:36.560Z", "location_count": 6, "location_summary": "Los Angeles, California • Denver, Colorado • Jacksonville, Florida + 3 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Denver", "state": "Colorado" }, { "city": "Jacksonville", "state": "Florida" }, { "city": "Nashville", "state": "Tennessee" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT06325748" }, { "nct_id": "NCT03807063", "title": "Rivogenlecleucel Donor Lymphocyte Immunotherapy in Treating Patients With Recurrent Blood Cancers After Stem Cell Transplant", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Acute Bilineal Leukemia", "Myelodysplastic/Myeloproliferative Neoplasm", "Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable", "Myeloproliferative Neoplasm", "Recurrent Acute Biphenotypic Leukemia", "Recurrent Acute Lymphoblastic Leukemia", "Recurrent Acute Myeloid Leukemia", "Recurrent Blastic Plasmacytoid Dendritic Cell Neoplasm", "Recurrent Chronic Lymphocytic Leukemia", "Recurrent Chronic Myelogenous Leukemia, BCR-ABL1 Positive", "Recurrent Chronic Myelomonocytic Leukemia", "Recurrent Myelodysplastic Syndrome" ], "interventions": [ { "name": "Rivogenlecleucel", "type": "BIOLOGICAL" }, { "name": "Rimiducid", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Fred Hutchinson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Months", "maximum_age": null, "sex": "ALL", "summary": "12 Months and older" }, "enrollment_count": 0, "start_date": "2020-01-02", "completion_date": "2021-12-31", "has_results": false, "last_update_posted_date": "2020-08-14", "last_synced_at": "2026-05-22T07:49:36.560Z", "location_count": 1, "location_summary": "Seattle, Washington", "locations": [ { "city": "Seattle", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT03807063" }, { "nct_id": "NCT00026520", "title": "Interferon Alfa and Thalidomide in Treating Patients With Stage IV Melanoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Melanoma (Skin)" ], "interventions": [ { "name": "recombinant interferon alfa", "type": "BIOLOGICAL" }, { "name": "thalidomide", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "SWOG Cancer Research Network", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": null, "start_date": "2001-11", "completion_date": "2006-04", "has_results": false, "last_update_posted_date": "2013-06-24", "last_synced_at": "2026-05-22T07:49:36.560Z", "location_count": 94, "location_summary": "Mobile, Alabama • Phoenix, Arizona • Tucson, Arizona + 60 more", "locations": [ { "city": "Mobile", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT00026520" }, { "nct_id": "NCT06349642", "title": "Immune Checkpoint Inhibitor Response in Solid Tumors Using a Live Tumor Diagnostic Platform", "overall_status": "RECRUITING", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Early Stage Triple-Negative Breast Carcinoma", "Metastatic Bladder Urothelial Carcinoma", "Metastatic Cervical Carcinoma", "Metastatic Clear Cell Renal Cell Carcinoma", "Metastatic Colorectal Carcinoma", "Metastatic Endometrial Carcinoma", "Metastatic Esophageal Carcinoma", "Metastatic Liver Carcinoma", "Metastatic Lung Non-Small Cell Carcinoma", "Metastatic Malignant Skin Neoplasm", "Metastatic Malignant Solid Neoplasm", "Resectable Lung Non-Small Cell Carcinoma", "Early Stage Lung Non-Small Cell Carcinoma", "Resectable Malignant Solid Neoplasm", "Resectable Triple-Negative Breast Carcinoma", "Stage III Renal Cell Cancer AJCC v8", "Stage IV Cervical Cancer AJCC v8", "Stage IV Renal Cell Cancer AJCC v8", "Stage IV Uterine Corpus Carcinoma or Carcinosarcoma AJCC v8", "Recurrent Cervical Carcinoma", "Recurrent Colorectal Carcinoma", "Recurrent Endometrial Carcinoma", "Recurrent Esophageal Carcinoma", "Recurrent Liver Carcinoma", "Recurrent Lung Non-Small Cell Carcinoma", "Recurrent Malignant Skin Neoplasm", "Recurrent Malignant Solid Neoplasm" ], "interventions": [ { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Tissue Collection", "type": "PROCEDURE" } ], "intervention_types": [ "PROCEDURE" ], "sponsor": "Mayo Clinic", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 324, "start_date": "2024-04-24", "completion_date": "2027-05", "has_results": false, "last_update_posted_date": "2026-03-12", "last_synced_at": "2026-05-22T07:49:36.560Z", "location_count": 3, "location_summary": "Phoenix, Arizona • Jacksonville, Florida • Rochester, Minnesota", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Jacksonville", "state": "Florida" }, { "city": "Rochester", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT06349642" }, { "nct_id": "NCT00499733", "title": "Cyclophosphamide and Cryoablation in Treating Patients With Advanced or Metastatic Epithelial Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "EARLY_PHASE1" ], "conditions": [ "Cancer" ], "interventions": [ { "name": "cyclophosphamide", "type": "DRUG" }, { "name": "Cryoablation", "type": "DEVICE" } ], "intervention_types": [ "DRUG", "DEVICE" ], "sponsor": "Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "120 Years", "sex": "ALL", "summary": "18 Years to 120 Years" }, "enrollment_count": 19, "start_date": "2007-06", "completion_date": "2013-01-09", "has_results": false, "last_update_posted_date": "2019-01-18", "last_synced_at": "2026-05-22T07:49:36.560Z", "location_count": 1, "location_summary": "Baltimore, Maryland", "locations": [ { "city": "Baltimore", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT00499733" } ] }